3-benzyloxy-5-methoxy-1-benzo[b]thiophene-2-carboxylic acid | 722517-00-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 3-benzyloxy-5-methoxy-1-benzo[b]thiophene-2-carboxylic acid
• 英文别名: 3-benzyloxybenzo[b]thiophene-2-carboxylic acid；3-benzyloxy-1-benzothiophene-2-carboxylic acid；3-benzyloxy-1-benzo[b]thiophene-2-carboxylic acid；3-phenylmethoxy-1-benzothiophene-2-carboxylic acid
• CAS: 722517-00-2
• 化学式: C₁₆H₁₂O₃S
• 分子量: 284.335
• InChiKey: NOKHKPQKBZRXFG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  74.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-benzyloxy-5-methoxy-1-benzo[b]thiophene-2-carboxylic acid 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 N-(3-acetamidobenzyl)-3-benzyloxybenzothiophene-2-carboxamide
  参考文献：
  名称：

  Benzothiophene-2-carboxamide derivatives as SENPs inhibitors with selectivity within SENPs family

  摘要：

  The SUMO (small ubiquitin-related modifier)-specific proteases (SENPs) are responsible for the cleavage of SUMO from its target proteins, thus play important roles in the dynamic SUMOylation and deSU-MOylation processes. SENPs are related to a variety of human diseases including cancer and represent a new class of potential therapeutic targets with mechanism of action that is likely to be different from that of current clinically used drugs. However, potent inhibitors that are selective within the SENPs family members still remain a challenge due to their high homology. In order to demonstrate the feasibility of developing selective inhibitors within the SENPs family, we chose SENP1/2/5 as representatives, aiming to identify inhibitors with selectivity among the members. Starting from a hit compound ZCL951 from virtual screening, a series of benzothiophene-2-carboxamide inhibitors were designed based on the protein structures of SENP1, 2, and 5. First, an unoccupied hydrophobic pocket was first identified which led to IC50 as low as 0.56 mu M. Furthermore, the ethylacetate 77 gave both submicromolar inhibitory activity and 33-fold selectivity for SENP2 versus SENP5. They are the most potent and selective nonpeptidic inhibitor reported so far for the SENPs family, as far as we are aware. Their structure-activity relationship was also discussed. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112553
• 作为产物：
  描述：

  3-羟基苯并[B]噻吩-2-羧酸甲酯 在 lithium hydroxide monohydrate 、 potassium carbonate 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 3-benzyloxy-5-methoxy-1-benzo[b]thiophene-2-carboxylic acid
  参考文献：
  名称：

  EP2926660

  摘要：

  公开号：

文献信息

• Accepting the Invitation to Open Innovation in Malaria Drug Discovery: Synthesis, Biological Evaluation, and Investigation on the Structure–Activity Relationships of Benzo[<i>b</i>]thiophene-2-carboxamides as Antimalarial Agents
  作者：Marco Pieroni、Elisa Azzali、Nicoletta Basilico、Silvia Parapini、Michal Zolkiewski、Claudia Beato、Giannamaria Annunziato、Agostino Bruno、Federica Vacondio、Gabriele Costantino

  DOI：10.1021/acs.jmedchem.6b01685

  日期：2017.3.9

  Malaria eradication is a global health priority, but current therapies are not always suitable for providing a radical cure. Artemisinin has paved the way for the current malaria treatment, the so-called Artemisinin-based Combination Therapy (ACT). However, with the detection of resistance to ACT, innovative compounds active against multiple parasite species and at multiple life stages are needed.

  消灭疟疾是全球卫生的重中之重，但是当前的治疗方法并不总是适合提供彻底的治疗方法。青蒿素为目前的疟疾治疗铺平了道路，所谓的基于青蒿素的联合疗法（ACT）。但是，随着对ACT的抗性的检测，需要对多种寄生虫物种具有多种生命周期且具有活性的创新化合物。葛兰素史克最近披露了内部图书馆的表型筛选结果，发表了400种抗疟药化学型的集合，称为“疟疾箱”。对数据集进行分析后，我们开展了一项药物化学研究活动，以定义一种释放化合物的结构-活性关系，该关系体现了苯并噻吩-2-羧酰胺核心。制备了35种化合物，本文报道了恶性疟原虫，毒性和代谢稳定性。
• Synthesis and Cannabinoid Activity of a Variety of 2,3-Substituted 1-Benzo[b]thiophen Derivatives and 2,3-Substituted Benzofuran: Novel Agonists for the CB1 Receptor
  作者：Gerard P. Moloney、James A. Angus、Alan D. Robertson、Martin J. Stoermer、Michael Robinson、Lucy Lay、Christine E. Wright、Ken McRae、Arthur Christopoulos

  DOI：10.1071/ch07412

  日期：——

  have discovered a novel series of compounds, which contain a 1-benzo[b]thiophen or a benzofuran group as the central aromatic group. Our investigation of this series of compounds has enhanced our understanding of the importance of binding sites within the CB1 receptor for favourable CB1 potency. Our understanding of these factors allowed us to modify the structure of a 1-benzothiophen derivative and improve

  已经进行了探索性的化学努力，以开发一系列新的化合物作为选择性 CB1 激动剂。希望这种类型的化合物在中风或颅脑外伤后的疼痛控制和脑缺血方面具有临床应用价值。我们在此报告旨在研究几类 1-苯并[b]噻吩和苯并呋喃衍生物作为新型 CB1 激动剂的药物化学研究。我们发现了一系列新的化合物，其中包含一个 1-苯并[b]噻吩或苯并呋喃基团作为中心芳族基团。我们对这一系列化合物的研究增强了我们对 CB1 受体内结合位点对有利 CB1 效力的重要性的理解。
• [EN] FC RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS<br/>[FR] COMPOSES ET COMPOSITIONS MODULANT LE RECEPTEUR FC
  申请人：ARTHRON LTD

  公开号：WO2004058747A1

  公开（公告）日：2004-07-15

  The present invention provides compounds capable of binding to an Fc receptor and modulating Fc receptor activity comprising a core lipophilic group in the form of an Aryl ring substituted with a group rich in p-electrons. The invention further provides for a method of treating an autoimmune disease involving Fc receptor activity using such compounds. A method for obtaining a compound which modulates Fc receptor activity is also provided, the method comprising: (a) providing or designing compounds having structural characteristics to fit in the groove of the FcϜRIIa structure; and (b) screening the compounds for modulating activity on the Fc receptor.

  本发明提供了能够结合到Fc受体并调节Fc受体活性的化合物，包括以芳基环形式的核心疏水基团，该芳基环被富含p-电子的基团取代。本发明还提供了一种治疗自身免疫疾病涉及Fc受体活性的方法，使用这种化合物。还提供了一种获取调节Fc受体活性的化合物的方法，该方法包括：(a)提供或设计具有结构特征以适应FcϜRIIa结构凹槽的化合物；和(b)筛选这些化合物以调节Fc受体活性。
• Fc Receptor Modulating Compounds and Compositions
  申请人：Hogarth Mark Phillip

  公开号：US20080146632A1

  公开（公告）日：2008-06-19

  The present invention provides compounds capable of binding to an Fc receptor and modulating Fc receptor activity comprising a core lipophilic group in the form of an Aryl zing substituted with a group rich in p-electrons. The invention further provides for a method of treating an autoimmune disease involving Fc receptor activity using such compounds. A method for obtaining a compound which modulates Fc receptor activity is also provided, the method comprising: (a) providing or designing compounds having structural characteristics to fit in the groove of the FcγRIIa structure; and (b) screening the compounds for modulating activity on the Fc receptor.

  本发明提供了一种能够结合到Fc受体并调节Fc受体活性的化合物，包括一个具有芳基锌的核心亲脂基团，该芳基锌被富含p电子的基团取代。本发明还提供了一种使用这些化合物治疗自身免疫性疾病的方法，该疾病涉及Fc受体活性。本发明还提供了一种获得调节Fc受体活性的化合物的方法，该方法包括：（a）提供或设计具有结构特征以适合FcγRIIa结构凹槽的化合物；和（b）筛选具有调节Fc受体活性的化合物。
• Fc RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS
  申请人：Hogarth Mark Phillip

  公开号：US20110144170A1

  公开（公告）日：2011-06-16

  The present invention provides compounds capable of binding to an Fc receptor and modulating Fc receptor activity comprising a core lipophilic group in the form of an Aryl zing substituted with a group rich in p-electrons. The invention further provides for a method of treating an autoimmune disease involving Fc receptor activity using such compounds. A method for obtaining a compound which modulates Fc receptor activity is also provided, the method comprising: (a) providing or designing compounds having structural characteristics to fit in the groove of the FcγRIIa structure; and (b) screening the compounds for modulating activity on the Fc receptor.

  本发明提供了一种能够结合Fc受体并调节Fc受体活性的化合物，包括一个具有芳基锌取代基的亲脂性核心基团，该基团被富含p电子的基团所取代。本发明还提供了一种治疗自身免疫性疾病的方法，该方法涉及使用这些化合物来调节Fc受体活性。还提供了一种获得调节Fc受体活性的化合物的方法，该方法包括：(a)提供或设计具有适合于FcγRIIa结构凹槽的结构特征的化合物；(b)筛选这些化合物以获得对Fc受体的调节活性。